Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

被引：1
|
作者：
Rueda, Antonio [1 ]
Calvo, Virginia [2 ]
Casanova, Maria [1 ]
Rodriguez-Abreu, Delvys [3 ]
Aguiar, David [4 ]
Llanos, Marta [5 ]
Alvarez, Ruth [6 ]
Martinez-Banaclocha, Natividad [7 ]
Alfaro, Jesus [8 ]
Quero, Cristina [9 ]
Blasco, Ana [10 ]
de la Cruz Merino, Luis [11 ]
Herrero, Joaquin [12 ]
Garcia-Arroyo, Francisco R. [13 ]
Provencio, Mariano [2 ]
机构：
[1] Hosp Costa Sol, Marbella, Spain
[2] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
[3] Hosp Insular, Las Palmas Gran Canaria, Las Palmas, Spain
[4] Hosp Dr Negrin, Las Palmas Gran Canaria, Las Palmas, Spain
[5] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[6] Hosp Virgen Salud, Toledo, Spain
[7] Hosp Gen Univ Elche, Alicante, Spain
[8] Oncologikoa, Donostia San Sebastian, Spain
[9] Hosp Univ Gen & Virgen Victoria, Malaga, Spain
[10] Hosp Gen Univ, Valencia, Spain
[11] Hosp Virgen Macarena, Seville, Spain
[12] Hosp Gen Univ Alicante, Alicante, Spain
[13] Complexo Hosp Univ Pontevedra, Pontevedra, Spain
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 06期
关键词：
NON-HODGKIN-LYMPHOMA; INDOLENT B-CELL; PLUS RITUXIMAB; MANTLE-CELL; 1ST-LINE TREATMENT; OPEN-LABEL; RELAPSED INDOLENT; MULTICENTER; OBINUTUZUMAB; THERAPY;
D O I：
10.1080/10428194.2018.1542147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1576 / 1579
页数：4
相关论文
共 29 条
  • [1] Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
    Penalver, Francisco-Javier
    Marquez, Jose-Antonio
    Duran, Soledad
    Giraldo, Pilar
    Martin, Alejandro
    Montalban, Carlos
    Sancho, Juan-Manuel
    Ramirez, Maria-Jose
    Terol, Maria-Jose
    Capote, Francisco-Javier
    Gutierrez, Antonio
    Sanchez, Blanca
    Lopez, Andres
    Salar, Antonio
    Rodriguez-Caravaca, Gil
    Canales, Miguel
    Caballero, Maria-Dolores
    Bello Lopez, Jose Luis
    Carbonell, Felix
    Ferrer Bordas, Secundino
    Font Lopez, Patricia
    Perez Persona, Ernesto
    Lopez Guillermo, Armando
    Hernandez Martin, Roberto
    Ramon Mayans, Jose
    Palomera, Luis
    Perez Ceballos, Elena
    Queizan Hernandez, Jose Antonio
    Riaza Grau, Rosalia
    de la Cruz, Fatima
    Sanchez Salinas, Andres
    CANCER MEDICINE, 2019, 8 (16): : 6955 - 6966
  • [2] Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
    Hess, Georg
    Wagner, Karola
    Keller, Ulrich
    La Rosee, Paul
    Atta, Johannes
    Huebel, Kai
    Lerchenmueller, Christian
    Schoendube, Daniel
    Witzens-Harig, Mathias
    Ruckes, Christian
    Medler, Christoph
    van Oordt, Christina
    Klapper, Wolfram
    Theobald, Matthias
    Dreyling, Martin
    HEMASPHERE, 2020, 4 (03):
  • [3] A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma
    Luminari, Stefano
    Goldaniga, Maria
    Cesaretti, Marina
    Orsucci, Lorella
    Tucci, Alessandra
    Pulsoni, Alessandro
    Salvi, Flavia
    Arcaini, Luca
    Carella, Angelo Michele
    Tedeschi, Alessandra
    Pinto, Antonello
    Stelitano, Caterina
    Baldini, Luca
    LEUKEMIA & LYMPHOMA, 2016, 57 (04) : 880 - 887
  • [4] Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
    Zaja, Francesco
    Ferrero, Simone
    Stelitano, Caterina
    Ferrari, Angela
    Salvi, Flavia
    Arcari, Annalisa
    Musuraca, Gerardo
    Botto, Barbara
    Spina, Michele
    Cellini, Claudia
    Patti, Caterina
    Liberati, Anna M.
    Minotto, Claudia
    Pileri, Stefano A.
    Ceccarelli, Manuela
    Volpetti, Stefano
    Ferranti, Antonella
    Drandi, Daniela
    Montechiarello, Elisa
    Ladetto, Marco
    Carmichael, James
    Fanin, Renato
    HAEMATOLOGICA, 2017, 102 (05) : E203 - E206
  • [5] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis
    Pouyiourou, M.
    Meyer, A.
    Stroux, A.
    Viardot, A.
    La Rosee, P.
    Maschmeyer, G.
    Kaempfe, D.
    Kahl, C.
    Vucinic, V.
    Monecke, A.
    Hirt, C.
    Weber, T.
    Meissner, J.
    Witzens-Harig, M.
    Boettcher, S.
    Schmalenberg, H.
    Marks, R.
    Prange-Krex, G.
    Kroschinsky, F.
    Hauf, E.
    Keller, U.
    Koch, K.
    Klapper, W.
    Herold, M.
    Scholz, Christian W.
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2821 - 2829
  • [6] A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma
    Park, Steven I.
    Grover, Natalie S.
    Olajide, Oludamilola
    Asch, Adam S.
    Wall, James G.
    Richards, Kristy L.
    Sobol, Anna L.
    Deal, Allison M.
    Ivanova, Anastasia
    Foster, Matthew C.
    Muss, Hyman B.
    Shea, Thomas C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (02) : 281 - 289
  • [7] Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group
    Provencio, Mariano
    Cruz Mora, Miguel A.
    Gomez-Codina, Jose
    Quero Blanco, Cristina
    Llanos, Marta
    Garcia-Arroyo, Francisco R.
    de la Cruz, Luis
    Guma Padro, Josep
    Delgado Perez, Juan R.
    Sanchez, Antonio
    Alvarez Cabellos, Ruth
    Rueda, Antonio
    LEUKEMIA & LYMPHOMA, 2014, 55 (01) : 51 - 55
  • [8] Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
    Davies, Andrew
    Merli, Francesco
    Mihaljevic, Biljana
    Mercadal, Santiago
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    Genevray, Magali
    Zharkov, Artem
    Dixon, Mark
    Brewster, Michael
    Barrett, Martin
    MacDonald, David
    LANCET HAEMATOLOGY, 2017, 4 (06): : E272 - E282
  • [9] Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US
    Guzauskas, Gregory F.
    Masaquel, Anthony
    Reyes, Carolina
    Bernaards, Coen
    Krivasi, Tania
    Veenstra, David L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) : 960 - 967
  • [10] Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design
    Kumar, Anita
    Casulo, Carla
    Joffe, Erel
    Moskowitz, Craig
    Gerecitano, John
    Moskowitz, Alison
    Younes, Anas
    Drullinsky, Pamela
    Drill, Esther
    Choma, Morgan
    Grieve, Clare
    Joseph, Ashlee
    Laraque, Leana
    Schick, Dylan
    Zelenetz, Andrew
    Hamlin, Paul
    LEUKEMIA & LYMPHOMA, 2022, 63 (12) : 2889 - 2896
123